Clinical Trials Logo

Withdrawal clinical trials

View clinical trials related to Withdrawal.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06066996 Recruiting - E-cigarette Use Clinical Trials

Evaluation of the Electronic Cigarette Withdrawal Syndrome

Start date: November 28, 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this project is to rigorously evaluate the nature of e-cigarette withdrawal in exclusive e-cigarette users during a monitored abstinence period and the role of nicotine in the expression of this withdrawal syndrome.

NCT ID: NCT05964738 Recruiting - Heart Failure Clinical Trials

Effect of Diuretics Withdrawal in Chronic Heart Failure With Reduced Ejection Fraction

REDICAE
Start date: December 19, 2022
Phase: Phase 2
Study type: Interventional

REDICAE trial was designed to evaluate the safety and tolerability of diuretics withdrawal in stable, euvolemic chronic outpatients with heart failure with reduced ejection fraction. It is a single-center, randomized, open-label, phase II clinical trial.

NCT ID: NCT04610476 Recruiting - Psoriatic Arthritis Clinical Trials

Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Start date: October 19, 2020
Phase: Phase 3
Study type: Interventional

The rationale for this study is to investigate whether in psoriatic arthritis (PsA) patients in stable remission a reduction or complete discontinuation of immunosuppressive therapy can be achieved in a treat-to-target approach while maintaining in remission. Due to the lack of reliable data that answers the question of how to safely reduce medication in which patients, this study will test a pragmatic treatment algorithm that can be applied in clinical practice and that offers a gradual reduction with escape strategies in order to facilitate the maintenance of remission.

NCT ID: NCT02249026 Recruiting - Withdrawal Clinical Trials

Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study

Start date: October 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Summary: There have been two published RCTs showing efficacy of buprenorphine treatment for NAS. However these trials excluded an estimated 22-47% of infants requiring pharmacologic treatment; those infants born to mothers with co-dependence on an opiate and a benzodiazepine. Although there are concerns, we anticipate that buprenorphine will be safe in this population. If it is safe, we can include these infants in the large double blind, double-dummy buprenorphine and clonidine vs. morphine and clonidine trial. If on the other hand, these infants have respiratory depression or other adverse events when buprenorphine is given, it will be important to report this study and caution the use of buprenorphine in these infants